Abstract
The author comments on a report in this issue of Cancer by investigators who used clinical response endpoints and chemoresistance testing to confirm the improved survival of women with hereditary ovarian carcinoma compared with women who had sporadic ovarian carcinoma. The possible use of BRCA mutation status to improve patient care, the future of translational research, and the difficulties in proceeding with large-scale prospective trials are among the topics discussed.
Original language | English |
---|---|
Pages (from-to) | 2127-2129 |
Number of pages | 3 |
Journal | Cancer |
Volume | 97 |
Issue number | 9 |
DOIs | |
State | Published - May 1 2003 |
Keywords
- BRCA1 Protein/genetics
- BRCA2 Protein/genetics
- Disease-Free Survival
- Female
- Germ-Line Mutation
- Humans
- Ovarian Neoplasms/genetics
- Survival Rate